• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Mirum Pharmaceuticals, Inc. - common stock (NQ:MIRM)

44.46 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, May 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 8,108
Open 44.46
Bid (Size) 40.00 (1)
Ask (Size) 53.40 (1)
Prev. Close 44.46
Today's Range 44.46 - 44.46
52wk Range 23.83 - 54.23
Shares Outstanding 38,297,975
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Mirum Pharmaceuticals Appoints Doug Sheehy, JD, as Chief Legal Officer
May 19, 2025
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
May 14, 2025
From Mirum Pharmaceuticals, Inc.
Via Business Wire

Performance

YTD
+5.8%
+5.8%
1 Month
+7.6%
+7.6%
3 Month
-12.7%
-12.7%
6 Month
+0.4%
+0.4%
1 Year
+79.6%
+79.6%

More News

Read More
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 09, 2025
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Earnings Scheduled For May 7, 2025
May 07, 2025
Via Benzinga
Preview: Mirum Pharmaceuticals's Earnings
May 06, 2025
Via Benzinga
Earnings Scheduled For February 26, 2025
February 26, 2025
Via Benzinga
Beyond The Numbers: 4 Analysts Discuss Mirum Pharmaceuticals Stock
May 09, 2025
Via Benzinga
Volixibat Data from Mirum’s VANTAGE PBC Study Showcased at EASL
May 09, 2025
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Mirum Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update
May 07, 2025
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Mirum Pharmaceuticals to Announce First Quarter 2025 Financial Results and Host Conference Call on May 7, 2025
April 30, 2025
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Mirum Pharmaceuticals to Present Data at Upcoming Medical Congresses
April 28, 2025
From Mirum Pharmaceuticals, Inc.
Via Business Wire
FDA Approves Mirum Pharmaceuticals’ Drug For Rare Liver Disease Patients In Tablet Form: Retail Stays Bullish
April 14, 2025
Via Stocktwits
Exposures Product Safety
Mirum’s LIVMARLI Now FDA Approved in Tablet Formulation
April 14, 2025
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 10, 2025
From Mirum Pharmaceuticals, Inc.
Via Business Wire
LIVMARLI Now Approved in Japan for ALGS and PFIC
March 27, 2025
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 10, 2025
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Update
February 26, 2025
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Mirum’s CTEXLI™ (chenodiol) Tablets Receives FDA Approval for Treatment of Cerebrotendinous Xanthomatosis (CTX)
February 24, 2025
From Mirum Pharmaceuticals, Inc.
Via Business Wire
FDA Approves Mirum Pharmaceuticals' Drug As First For Genetic Disorder With Inability To Break-Down Cholesterol
February 21, 2025
Via Benzinga
Exposures Product Safety
Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2024 Financial Results and Host Conference Call on February 26, 2025
February 19, 2025
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 10, 2025
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Mirum Pharmaceuticals Announces Preliminary Unaudited 2024 Net Product Sales and Cash Balance and Provides Corporate Updates
January 13, 2025
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 10, 2025
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Mirum Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
January 06, 2025
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 10, 2024
From Mirum Pharmaceuticals, Inc.
Via Business Wire

Frequently Asked Questions

Is Mirum Pharmaceuticals, Inc. - common stock publicly traded?
Yes, Mirum Pharmaceuticals, Inc. - common stock is publicly traded.
What exchange does Mirum Pharmaceuticals, Inc. - common stock trade on?
Mirum Pharmaceuticals, Inc. - common stock trades on the Nasdaq Stock Market
What is the ticker symbol for Mirum Pharmaceuticals, Inc. - common stock?
The ticker symbol for Mirum Pharmaceuticals, Inc. - common stock is MIRM on the Nasdaq Stock Market
What is the current price of Mirum Pharmaceuticals, Inc. - common stock?
The current price of Mirum Pharmaceuticals, Inc. - common stock is 44.46
When was Mirum Pharmaceuticals, Inc. - common stock last traded?
The last trade of Mirum Pharmaceuticals, Inc. - common stock was at 05/30/25 04:00 PM ET
What is the market capitalization of Mirum Pharmaceuticals, Inc. - common stock?
The market capitalization of Mirum Pharmaceuticals, Inc. - common stock is 1.70B
How many shares of Mirum Pharmaceuticals, Inc. - common stock are outstanding?
Mirum Pharmaceuticals, Inc. - common stock has 2B shares outstanding.
Site Logo
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap